Your session is about to expire
← Back to Search
SGLT2 Inhibitor
Treatment for Myocardial Infarction (DAPA STEMI Trial)
Phase 3
Waitlist Available
Led By Michel LeMay, MD
Research Sponsored by Ottawa Heart Institute Research Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Ischemic chest discomfort of ≥30 minutes duration
Anterior STEMI with ST-segment elevation ≥2mm (0.2 mV) in each of at least 2 contiguous precordial leads (V1-V6)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months, and 6 months
Awards & highlights
DAPA STEMI Trial Summary
This trial will test if SGLT2i can help reduce infarct size in patients having a heart attack & referred for PPCI. Cardiac MRI will measure the effect.
Who is the study for?
This trial is for patients who have had a severe type of heart attack known as STEMI and are going to undergo primary percutaneous coronary intervention (PPCI). The specific details about who can join or must avoid the trial aren't provided here.Check my eligibility
What is being tested?
The study is testing if a diabetes medication called Dapagliflozin can reduce the damage to the heart muscle in patients with STEMI. Participants will be randomly assigned to receive either Dapagliflozin or a placebo, alongside their standard treatment.See study design
What are the potential side effects?
While not specified here, common side effects of Dapagliflozin may include yeast infections, urinary tract infections, increased urination, and potential risk of dehydration.
DAPA STEMI Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have had chest pain lasting 30 minutes or more.
Select...
I had a severe heart attack with specific EKG changes.
DAPA STEMI Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 months, and 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months, and 6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Infarct Size
Secondary outcome measures
Acute Kidney Injury
Cardiogenic Shock
Multiple Cardiac Adverse Events (MACE)
DAPA STEMI Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: TreatmentExperimental Treatment2 Interventions
Dapagliflozin 10mg daily X 7 days
Group II: PlaceboPlacebo Group1 Intervention
Placebo daily X 7 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dapagliflozin 10mg Tab
2022
Completed Phase 4
~970
CMR
2014
Completed Phase 4
~240
Find a Location
Who is running the clinical trial?
Ottawa Heart Institute Research CorporationLead Sponsor
188 Previous Clinical Trials
92,180 Total Patients Enrolled
6 Trials studying Myocardial Infarction
3,595 Patients Enrolled for Myocardial Infarction
Michel LeMay, MDPrincipal InvestigatorOttawa Heart Institute Research Corporation
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Has this intervention achieved FDA sanction?
"Our organisation believes this therapy is relatively secure, ranking it a 3 on our scale. This proof of concept trial has indicated efficacy and past research highlights its safety profile."
Answered by AI
Are there still open enrolment spots for this experimental research?
"According to records on clinicaltrials.gov, this trial has ceased recruiting new patients since its last update on 12/7/2023; though there are still 339 other trials in need of participants."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger